The DOI matches its Crossref record; 227 of the 231 references it cites were found in a registry or an index.
Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential
Abstract
Muscle wasting is associated with a wide range of catabolic diseases. This debilitating loss of muscle mass and functional capacity reduces the quality of life and increases the risks of morbidity and mortality. Major progress has been made in understanding the biochemical mechanisms and signaling pathways regulating muscle protein balance under normal conditions and the enhanced protein loss in atrophying muscles. It is now clear that activation of myostatin/activin signaling is critical in triggering the accelerated muscle catabolism that causes muscle loss in multiple disease states. Binding of myostatin and activin to the ActRIIB receptor complex on muscle cell membrane leads to activation of Smad2/3-mediated transcription, which in turn stimulates FoxO-dependent transcription and enhanced muscle protein breakdown via ubiquitin-proteasome system and autophagy. In addition, Smad activation inhibits muscle protein synthesis by suppressing Akt signaling. Pharmacological blockade of the myostatin/activin-ActRIIB pathway has been shown to prevent or reverse the loss of muscle mass and strength in various disease models including cancer cachexia and renal failure. Moreover, it can markedly prolong the lifespan of animals with cancer-associated muscle loss. Furthermore, inhibiting myostatin/activin actions also improves insulin sensitivity, reduces excessive adiposity, attenuates systemic inflammation, and accelerates bone fracture healing in disease models. Based on these exciting advances, the potential therapeutic benefits of myostatin/activin antagonism are now being tested in multiple clinical settings. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the ability to modulate the Smad, FOXO and AKT pathways, the interaction between myostatin and physical exercise also appears to occur through the transcription factor peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) in muscle, which in turn is stimulated by exercise (Han et al., 2013).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Han et al., 2013
In the citing paper
“TGFβ-like ligands myostatin (GDF-8) and Activin A are negative regulators of skeletal muscle mass.”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [14]
In the citing paper
“The PI3K/Akt/mTOR signaling axis is well known to regulate anabolic processes, including increasing protein synthesis to support muscle hypertrophy [14].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [14]
In the citing paper
“These ligands signal via the activin type II A and B receptors (ActRII) which complex with transmembrane type I activin receptor-like kinases (ALK4 or ALK5) [14].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [14]
In the citing paper
“Engagement of these receptors leads to phosphorylation of Smad proteins downstream regulation of gene expression, and decreased IGF-1 signaling via Akt [14].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [14]
In the citing paper
“Mechanistically, ActRII inhibition is thought to induce skeletal muscle hypertrophy by reducing Smad2/3 activity and elevating Akt signaling [14,16].”
From Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism (2024) · cites this paper as [14]
Citations
Cites
1 retracted
Lokireddy, S., Wijesoma, I. W., Teng, S., Bonala, S., Gluckman, P. D., McFarlane, C., Sharma, M., & Kambadur, R. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.005 · Cited by 154
RetractedDefinition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I. G., Bruera, E. D., Fainsinger, R. L., Jatoi, A., Loprinzi, C. L., Macdonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 6,020
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
SATELLITE CELL OF SKELETAL MUSCLE FIBERS
Mauro, A. (1961) · The Journal of Cell Biology · doi:10.1083/jcb.9.2.493 · Cited by 3,683
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,239
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Self-citationPax7 Is Required for the Specification of Myogenic Satellite Cells
Seale, P., Sabourin, L. A., Girgis-Gabardo, A., Mansouri, A., Gruß, P., & Rudnicki, M. A. (2000) · Cell · doi:10.1016/s0092-8674(00)00066-0 · Cited by 2,345
Evans, W., Morley, J., Argilés, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-zadeh, K., Lochs, H., Mantovani, G., et al. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2008.06.013 · Cited by 2,341
Self-citation
Cited by
Sorted by citations
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Self-citationMechanisms of muscle wasting in chronic kidney disease
Wang, X. H., & Mitch, W. E. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.112 · Cited by 630
Self-citationSarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Role of Myokines in Regulating Skeletal Muscle Mass and Function
Lee, J. H., & Jun, H.-S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00042 · Cited by 432
Leal, L. G., Lopes, M. A., & Batista, M. L. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01307 · Cited by 382
“In addition to the ability to modulate the Smad, FOXO and AKT pathways, the interaction between myostatin and physical exercise also appears to occur through the transcription factor peroxisome proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) in muscle, which in turn is stimulated by exercise (Han e…”
BackgroundMechanisms of metabolic dysfunction in cancer-associated cachexiaPreprint
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 344
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications
Ostrovidov, S., Hosseini, V., Ahadian, S., Fujie, T., Parthiban, S. P., Ramalingam, M., Bae, H., Kaji, H., & Khademhosseini, A. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0534 · Cited by 302
A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease
Marty, E., Liu, Y., Samuel, A. M., Or, O., & Lane, J. (2017) · Bone · doi:10.1016/j.bone.2017.09.008 · Cited by 310
Systemic Organ Wasting Induced by Localized Expression of the Secreted Insulin/IGF Antagonist ImpL2
Kwon, Y. V., Song, W., Droujinine, I. A., Hu, Y., Asara, J. M., & Perrimon, N. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.02.012 · Cited by 278
Environmental Enteropathy, Oral Vaccine Failure and Growth Faltering in Infants in Bangladesh
Naylor, C., Lu, M., Haque, R., Mondal, D., Buonomo, E. L., Nayak, U., Mychaleckyj, J. C., Kirkpatrick, B. D., Colgate, E. R., Carmolli, M. P., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.09.036 · Cited by 267
Bhanji, R. A., Narayanan, P., Allen, A. M., Malhi, H., & Watt, K. D. S. (2017) · Hepatology · doi:10.1002/hep.29420 · Cited by 259
Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer
Jung, B. H., Staudacher, J. J., & Beauchamp, D. R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.10.015 · Cited by 250
Silva, K. A. S., Dong, J., Dong, Y., Dong, Y., Schor, N., Tweardy, D. J., Zhang, L., & Mitch, W. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641514 · Cited by 229
Self-citationDevelopment of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Sugo, T., Terada, M., Oikawa, T., Miyata, K., Nishimura, S., Kenjo, E., Ogasawara-Shimizu, M., Makita, Y., Imaichi, S., Murata, S., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.036 · Cited by 233
Willems, S. M., Wright, D. J., Day, F. R., Trajanoska, K., Joshi, P. K., Morris, J. A., Matteini, A. M., Garton, F. C., Grarup, N., Oskolkov, N., et al. (2017) · Nature Communications · doi:10.1038/ncomms16015 · Cited by 220
Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis
Bunchorntavakul, C., & Reddy, K. R. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15571 · Cited by 230
Exercise-Induced Myokines With Therapeutic Potential for Muscle Wasting
Piccirillo, R. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00287 · Cited by 197
Stenvinkel, P., Carrero, J. J., von Walden, F., Ikizler, T. A., & Nader, G. A. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv122 · Cited by 193
Activin A more prominently regulates muscle mass in primates than does GDF8
Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms15153 · Cited by 185
Camporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak, M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525795113 · Cited by 184
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential
Martin, T. G., Juarros, M. A., & Leinwand, L. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00806-6 · Cited by 182
Nutrition and Muscle in Cirrhosis
Anand, A. C. (2017) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2017.11.001 · Cited by 182
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease
Wang, X. H., Mitch, W. E., & Price, S. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00498-0 · Cited by 182
Self-citationMuscle-bone interactions: From experimental models to the clinic? A critical update
Laurent, M. R., Dubois, V., Claessens, F., Verschueren, S., Vanderschueren, D., Gielen, E., & Jardí, F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.10.017 · Cited by 156
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
Smad3 Induces Atrogin-1, Inhibits mTOR and Protein Synthesis, and Promotes Muscle Atrophy In Vivo
Goodman, C. A., McNally, R. M., Hoffmann, F. M., & Hornberger, T. A. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1194 · Cited by 152
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Myokines in skeletal muscle physiology and metabolism: Recent advances and future perspectives
Das, D. K., Graham, Z. A., & Cardozo, C. P. (2020) · Acta Physiologica · doi:10.1111/apha.13367 · Cited by 129
Nunn, E., Jaiswal, N., Gavin, M., Uehara, K., Stefkovich, M., Drareni, K., Calhoun, R., Lee, M., Holman, C. D., Baur, J. A., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101880 · Cited by 126
Dubois, V., Laurent, M. R., Sinnesael, M., Cielen, N., Helsen, C., Clinckemalie, L., Spans, L., Gayan‐Ramirez, G., Deldicque, L., Hespel, P., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-249748 · Cited by 128
Estrogen Receptor β as a Pharmaceutical Target
Warner, M. N., Huang, B., & Gustafsson, J.-Α. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.006 · Cited by 118
Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions
Watanabe, H., Enoki, Y., & Maruyama, T. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00513 · Cited by 130
Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Gallot, Y. S., Durieux, A., Castells, J., Desgeorges, M. M., Vernus, B., Plantureux, L., Rémond, D., Jahnke, V. E., Lefai, É., Dardevet, D. P., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0057 · Cited by 123
Sarcopenia: Ammonia metabolism and hepatic encephalopathy
Jindal, A., & Jagdish, R. K. (2019) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0015 · Cited by 117
Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression
Huang, Q., Wu, M., Wu, X., Zhang, Y., & Xia, Y. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188761 · Cited by 124
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy
Long, K. K., O’Shea, K. M., Khairallah, R. J., Howell, K., Paushkin, S. V., Chen, K. S., Cote, S. M., Webster, M. T., Stains, J. P., Treece, E. R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy382 · Cited by 120
Yang, Y. J., & Kim, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052604 · Cited by 119
Mechanisms of Cachexia in Chronic Disease States
Yoshida, T., & Delafontaine, P. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000511 · Cited by 117
Role of microRNAs in skeletal muscle hypertrophy
Hitachi, K., & Tsuchida, K. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00408 · Cited by 106
Inactivating hepatic follistatin alleviates hyperglycemia
Tao, R., Wang, C., Stöhr, O., Qiu, W., Hu, Y., Miao, J., Dong, X. C., Leng, S., Stefater, M., Stylopoulos, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0048-0 · Cited by 104
Ubiquitin-proteasome pathway in skeletal muscle atrophy
Pang, X., Zhang, P., Chen, X., & Liu, W. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1289537 · Cited by 120
Hofmann, M., Schober-Halper, B., Oesen, S., Franzke, B., Tschan, H., Bachl, N., Strasser, E.-M., Quittan, M., Wagner, K., & Wessner, B. (2016) · European Journal of Applied Physiology · doi:10.1007/s00421-016-3344-8 · Cited by 106
Molecular pathways: cachexia signaling-A targeted approach to cancer treatment
Miyamoto, Y., Hanna, D. L., Zhang, W., Baba, H., & Lenz, H.-J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0495 · Cited by 111
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Kuchay, M. S., Martínez‐Montoro, J. I., Choudhary, N. S., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Biomedicines · doi:10.3390/biomedicines9101346 · Cited by 105
van Vugt, J. L. A., Braam, H. J., van Oudheusden, T. R., Vestering, A., Bollen, T. L., Wiezer, M. J., de Hingh, I. H. J. T., van Ramshorst, B., & Boerma, D. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4429-z · Cited by 98
Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
de Sire, R., Rizzatti, G., Ingravalle, F., Pizzoferrato, M., Petito, V., Lopetuso, L. R., Graziani, C., Alessandro de, S. I. R. E., Mentella, M. C., Mele, M. C., et al. (2018) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.18.02511-4 · Cited by 93
Emerging role of myostatin and its inhibition in the setting of chronic kidney disease
Verzola, D., Barisione, C., Picciotto, D., Garibotto, G., & Koppe, L. (2018) · Kidney International · doi:10.1016/j.kint.2018.10.010 · Cited by 95
Bajikar, S. S., Wang, C., Borten, M. A., Pereira, E. J., Atkins, K. A., & Janes, K. A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.10.027 · Cited by 87
Cole, C. L., Kleckner, I. R., Jatoi, A., Schwarz, E. M., & Dunne, R. F. (2018) · JCSM Clinical Reports · doi:10.17987/jcsm-cr.v3i2.65 · Cited by 84
Sarcopenic obesity: Myokines as potential diagnostic biomarkers and therapeutic targets?
Guo, A., Li, K., & Xiao, Q. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111022 · Cited by 83
Abati, E., Manini, A., Comi, G. P., & Corti, S. P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04408-w · Cited by 85
Activin A induces skeletal muscle catabolism via p38β mitogen‐activated protein kinase
Ding, H. J., Zhang, G., Sin, K. W. T., Liu, Z., Lin, R., Li, M., & Li, Y. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12145 · Cited by 86
The Role of the Skeletal Muscle Secretome in Mediating Endurance and Resistance Training Adaptations
Leuchtmann, A. B., Adak, V., Dilbaz, S., & Handschin, C. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.709807 · Cited by 84
Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease
Bhanji, R. A., Montaño‐Loza, A. J., & Watt, K. D. S. (2019) · Hepatology · doi:10.1002/hep.30686 · Cited by 82
Interaction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
Effect of Various Exercise Regimens on Selected Exercise-Induced Cytokines in Healthy People
Domin, R., Dadej, D., Pytka, M., Zybek-Kocik, A., Ruchała, M., & Guzik, P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18031261 · Cited by 79
“, directly by mechanisms independent from MSTN [44,45].”
BackgroundThe modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS
Gioia, S., Merli, M., Nardelli, S., Lattanzi, B., Pitocchi, F., Ridola, L., & Riggio, O. (2019) · Liver International · doi:10.1111/liv.14050 · Cited by 78
Hofmann, M., Halper, B., Oesen, S., Franzke, B., Stuparits, P., Tschan, H., Bachl, N., Strasser, E.-M., Quittan, M., Ploder, M., et al. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.02.008 · Cited by 74
Caloric restriction and exercise “mimetics”: ready for prime time
Handschin, C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.11.009 · Cited by 72
Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease
Altajar, S., & Baffy, G. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00065 · Cited by 79
Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications—A Narrative Review
Cheng, T.-C., Huang, S.-H., Kao, C., & Hsu, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116047 · Cited by 92
Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management
Siff, T. E., Parajuli, P., Razzaque, M. S., & Atfi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.03.007 · Cited by 73
Bhanji, R. A., Carey, E. J., Yang, L., & Watt, K. D. S. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.004 · Cited by 66
Ageta, H., & Tsuchida, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03246-7 · Cited by 67
SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a DNA-binding-dependent manner
Bollinger, L. M., Witczak, C. A., Houmard, J. A., & Brault, J. J. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00391.2013 · Cited by 67
Obesity Paradox, Cachexia, Frailty, and Heart Failure
Lavie, C. J., Schutter, A. D., Alpert, M., Mehra, M. R., Milani, R. V., & Ventura, H. O. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.12.002 · Cited by 65
Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration
Lattanzi, B., D’Ambrosio, D., & Merli, M. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.04.007 · Cited by 65
Generation of biallelic knock-out sheep via gene-editing and somatic cell nuclear transfer
Li, H., Wang, G., Hao, Z., Zhang, G., Qing, Y., Liu, S., Qing, L., Pan, W., Chen, L., Liu, G., et al. (2016) · Scientific Reports · doi:10.1038/srep33675 · Cited by 63
Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia
Parajuli, P., Kumar, S., Loumaye, A., Singh, P., Eragamreddy, S., Nguyen, T. L., Ozkan, S., Razzaque, M. S., Prunier, C., Thissen, J.-P., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.05.026 · Cited by 58
Follistatins in glucose regulation in healthy and obese individuals
Perakakis, N., Kokkinos, A. D., Peradze, N., Tentolouris, N., Ghaly, W., Tsilingiris, D., Alexandrou, A. P., & Mantzoros, C. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13572 · Cited by 56
The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia
Lan, X., Deng, C., Wang, Q., Zhao, L., Jiao, B., & Xiang, Y. (2024) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2024.114513 · Cited by 61
Novel therapeutic options for cachexia and sarcopenia
Molfino, A., Amabile, M. I., Fanelli, F. R., & Muscaritoli, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1208168 · Cited by 54
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Crawford, T. O., Darras, B. T., Day, J., Young, S. D., Duong, T., Nelson, L. L., Barrett, D., Song, G., Bilic, S., Cote, S. M., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209151 · Cited by 60
Perakakis, N., Mougios, V., Fatouros, I., Siopi, A., Draganidis, D., Peradze, N., Ghaly, W., & Mantzoros, C. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01056 · Cited by 52
Mechanisms of protein balance in skeletal muscle
Anthony, T. G. (2016) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2016.02.012 · Cited by 59
Iskenderian, A., Liu, N., Deng, Q., Huang, Y. L., Shen, C., Palmieri, K. J., Crooker, R., Lundberg, D. M., Kastrapeli, N., Pescatore, B., et al. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0180-z · Cited by 57
Verzola, D., Milanesi, S., Bertolotto, M. B., Garibaldi, S., Villaggio, B., Brunelli, C., Balbi, M., Ameri, P., Montecucco, F., Palombo, D., et al. (2017) · Scientific Reports · doi:10.1038/srep46362 · Cited by 52
Sun, R., Zhang, S., Hu, W., Lü, X. Q., Lou, N., Zhen-de, Y., Chen, S., Zhang, X., & Yang, H. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00344.2015 · Cited by 51
Myostatin Is Associated With Cognitive Decline in an Animal Model of Alzheimer’s Disease
Lin, Y.-S., Lin, F.-Y., & Hsiao, Y. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1201-y · Cited by 48
Development of Pharmacotherapies for the Treatment of Sarcopenia
Rooks, D., & Roubenoff, R. (2019) · The Journal of Frailty & Aging · doi:10.14283/jfa.2019.11 · Cited by 51
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Barrett, D., Bilic, S., Chyung, Y. H., Cote, S. M., Iarrobino, R., Kacena, K. A., Kalra, A. V., Long, K. K., Nomikos, G. G., Place, A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01757-z · Cited by 47
Kato, H., Watanabe, H., Imafuku, T., Arimura, N., Fujita, I., Noguchi, I., Tanaka, S., Nakano, T., Tokumaru, K., Enoki, Y., et al. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12786 · Cited by 46
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy
Samant, S. A., Kanwal, A., Pillai, V. B., Bao, R., & Gupta, M. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-10838-5 · Cited by 46
Lee, E. J., Ahmad, S. S., Lim, J. H., Ahmad, K., Shaikh, S., Lee, Y., Park, S. J., Jin, J., Lee, Y., & Choi, I. (2021) · Cells · doi:10.3390/cells10082083 · Cited by 46
Chen, M.-C., Chen, Y.-L., Lee, C.-F., Hung, C.-H., & Chou, T.-C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143594 · Cited by 45
Desgeorges, M. M., Devillard, X., Toutain, J., Castells, J., Divoux, D., Arnould, D., Haqq, C. M., Bernaudin, M., Durieux, A., Touzani, O., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13912-0 · Cited by 44
GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
Pantazopoulos, D., Gouveri, E., Papazoglou, D., & Παπάνας, Ν. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112924 · Cited by 47
Sepulveda, P. V., Lamon, S., Hagg, A., Thomson, R. E., Winbanks, C. E., Qian, H., Bruce, C. R., Russell, A. P., & Gregorevic, P. (2015) · Scientific Reports · doi:10.1038/srep17535 · Cited by 45
IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway
Liu, D., Qiao, X., Ge, Z., Shang, Y., Li, Y., Wang, W., Chen, M., Si, S., & Chen, S. (2019) · Skeletal Muscle · doi:10.1186/s13395-019-0193-2 · Cited by 42
Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice
Sherif, O. E., Dhaliwal, A., Newsome, P. N., & Armstrong, M. J. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1731303 · Cited by 40
The clinical relevance and mechanism of skeletal muscle wasting
Duan, K., Gao, X., & Zhu, D. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.07.029 · Cited by 44
Muscle wasting: an overview of recent developments in basic research
Palus, S., von Haehling, S., & Springer, J. (2014) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-014-0157-7 · Cited by 42
Muscle Atrophy in Chronic Kidney Disease
Schardong, J., Marcolino, M. A. Z., & Plentz, R. D. M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_18 · Cited by 41
Pettersen, K., Andersen, S. B., van der Veen, A., Nonstad, U., Hatakeyama, S., Lambert, C., Lach‐Trifilieff, E., Moestue, S. A., Kim, J., Grønberg, B. H., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12489 · Cited by 40
Saeki, C., & Tsubota, A. (2021) · Life · doi:10.3390/life11090899 · Cited by 42
Lawlor, M. W., Viola, M. G., Meng, H., Edelstein, R. V., Liu, F., Yan, K., Luna, E. J., Lerch-Gaggl, A., Hoffmann, R. G., Pierson, C. R., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.03.003 · Cited by 42
Roseno, S. L., Davis, P. R., Bollinger, L. M., Powell, J. J. S., Witczak, C. A., & Brault, J. J. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0037-y · Cited by 36
Metadata
- Authors
- Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L.
- Affiliations
- Amgen (United States) (US)
- Baylor College of Medicine (US)
- Harvard University (US)
- Corresponding author
- Han, H.Q.
- Venue
- The International Journal of Biochemistry & Cell Biology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 45
- Issue
- 10
- Pages
- 2333-2347
- ISSN
- 1357-2725 (ISSN-L)
- OpenAlex
- W1971189666
- Cited by
- 314
- References
- 231
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 25 · 2023: 12 · 2022: 26 · 2021: 26 · 2020: 32 · 2019: 29 · 2018: 21 · 2017: 20 · 2016: 22 · 2015: 17 · 2014: 23 · 2013: 9
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The International Journal of Biochemistry & Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Keywords
- myostatin, activin, muscle atrophy, Smad2/3 signaling, ubiquitin-proteasome system, autophagy, Akt signaling, muscle protein synthesis, cancer cachexia, renal failure, lifespan extension, insulin sensitivity, adiposity, systemic inflammation, fracture healing
- MeSH terms
- Animals, Humans, Muscle Proteins, Muscular Diseases, Signal Transduction, Muscle, Skeletal, Ubiquitin, Activins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Myostatin, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
